# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ann Richards (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML019-SYN
- Date: 2026-05-12
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rosalind Teague, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month bone health review before the first zoledronic acid infusion. **S**

## History of present illness

Ms. Richards returns three months after intake. She has taken vitamin D3 2000 units every day and keeps her calcium at about 1200 mg a day from food. She collected the 24-hour urine sample over the weekend, and the result came back this morning with her blood tests. Her routine dental examination three weeks ago found no problems and no dental work is planned. She finished all 16 sessions of the balance and strength program four days ago and now does the home program three times a week. She has had no falls. She has had no alcohol. She has read about the infusion and asked about the flu-like reaction that can follow a first dose. **S**

| Element | Detail |
|---|---|
| Vitamin D | D3 2000 units daily, no missed doses |
| Dental status | Routine examination three weeks ago; no work planned |
| Balance program | 16 of 16 sessions; home program three times a week |
| Falls | None |
| Recovery | No alcohol; no cravings |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Musculoskeletal | Negative | No bone, back, or thigh pain |
| Genitourinary | Negative | No kidney stones or urinary symptoms |
| Constitutional | Negative | No fever or recent illness; drinking plenty of fluid today |
| Psychiatric | Negative | Mood good; no cravings; no thoughts of self-harm |

4 systems reviewed. **S**

## Current medications

- Cholecalciferol (vitamin D3) 50 mcg (2000 units) oral tablet, one tablet daily **S**
- Zoledronic acid 5 mg in 100 mL intravenous infusion over 30 minutes, once every 12 months **S**
- Acetaminophen 500 mg oral tablet, two tablets every 6 hours as needed for aches or fever for up to three days after the infusion (no more than 3 g a day) **S**

## Allergies

- No known allergy **S**

## Objective

BP 120/74 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 66.4 kg; BMI 24.7 kg/m². All vital signs are synthetic.

25-hydroxyvitamin D: 38 ng/mL; Calcium: 9.5 mg/dL; Creatinine: 0.8 mg/dL; eGFR: 81 mL/min/1.73 m²; 24-hour urine calcium: 172 mg/(24.h). All results are synthetic.

## Change since baseline

- 25-hydroxyvitamin D: 24 ng/mL (low) at baseline, 38 ng/mL at this visit **S**
- Calcium: 9.4 mg/dL at baseline, 9.5 mg/dL at this visit **S**
- Creatinine: 0.8 mg/dL at baseline, 0.8 mg/dL at this visit **S**
- eGFR: 81 mL/min/1.73 m² at baseline, 81 mL/min/1.73 m² at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 66.4 kg |
| Mouth | Good dentition; no exposed bone |
| Gait and balance | Timed Up and Go 9 seconds; tandem stance 18 seconds |
| Spine | No tenderness or kyphosis |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Low bone mass with high fracture risk by FRAX, starting treatment** (M85.89). 25-hydroxyvitamin D 38 ng/mL, now at target. Calcium 9.5 mg/dL, creatinine 0.8 mg/dL, eGFR 81, and 24-hour urine calcium 172 mg, all normal, so the secondary-causes work-up is complete and shows no cause. Dental examination done. Ready for the first dose. **S**
   - Zoledronic acid 5 mg intravenously over 30 minutes in the infusion room today, after a glass of water.
   - Acetaminophen 1000 mg every 6 hours as needed for up to three days for the aches or fever that can follow a first dose.
   - Continue vitamin D3 2000 units daily and calcium from food.
   - Fasting morning CTX and calcium at the six-month visit.
2. **History of falls** (Z91.81). Balance much improved after the program: tandem stance 18 seconds, up from 8; Timed Up and Go 9 seconds, down from 11; no falls. **S**
   - Home balance and strength program three times a week.
3. **Alcohol use disorder in sustained remission** (F10.21). No alcohol or cravings. Safety reviewed: no thoughts of suicide or self-harm; the 988 Suicide & Crisis Lifeline is saved in her phone. **S**
   - Continue the recovery check at each visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | 25-hydroxyvitamin D | At baseline; after repletion until 30 ng/mL or more; then yearly | Completed today | 38 ng/mL, up from 24; at target; next yearly |
| Laboratory | Serum calcium before each intravenous antiresorptive dose | Before each zoledronic acid dose | Completed today | 9.5 mg/dL, normal; infusion given |
| Laboratory | Creatinine and eGFR before each zoledronic acid dose | Before each dose; do not give if creatinine clearance is below 35 mL/min | Completed today | Creatinine 0.8 mg/dL, eGFR 81 |
| Laboratory | 24-hour urine calcium | At diagnosis, before starting therapy | Completed today | 172 mg in 24 hours, normal; no hypercalciuria. Deviation: collected about three months after it was ordered, because the sample was missed before the four-week visit. No harm resulted: no drug was started until it was done, and the result is normal. Corrective action: baseline tests that need a home collection are now scheduled with the patient before she leaves the intake visit |
| Laboratory | Bone-turnover marker (fasting serum CTX) | Baseline, then 3 to 6 months after starting or changing therapy | Due | Baseline 560 pg/mL; repeat at the six-month visit, three months after today's dose |
| Medication safety | Dental examination before an antiresorptive | Before starting a bisphosphonate or denosumab | Completed today | Routine examination three weeks ago with no problems; no invasive dental work planned |
| Medication safety | First zoledronic acid dose | Yearly | Completed today | 5 mg intravenously over 30 minutes; acetaminophen plan given for the acute-phase reaction |
| Imaging | Central DXA of the spine and hip | Every 1 to 2 years on therapy until stable, on the same scanner | Up to date | Repeat two years after starting therapy |
| Examination | Standing height by stadiometer | Yearly; vertebral imaging again if height falls 2 cm or more | Up to date | 164.0 cm at intake; unchanged on today's vital signs |
| Examination | Fall-risk screen | Yearly, and with any fall | Completed today | After the balance program: Timed Up and Go 9 seconds, tandem stance 18 seconds; no falls |
| Survey | Calcium intake assessment | At baseline and yearly | Up to date | About 1200 mg a day from food |
| Medication safety | Drug-holiday eligibility | After 3 yearly zoledronic acid doses or 5 years of an oral bisphosphonate | Not indicated | First dose today; reassess after the third yearly dose |
| Self-management | Balance and strength exercise program | With a history of falls or impaired balance | Completed today | 16 of 16 sessions finished four days ago; home program three times a week |
| Self-management | Recovery check (alcohol, cravings, stress) | Every visit | Completed today | No alcohol; no cravings |
| Survey | Suicide-risk review and safety plan, with the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; the 988 Suicide & Crisis Lifeline is saved in her phone |

## Goal progress

- Total calcium intake of about 1200 mg a day, mostly from food, by the four-week visit. Outcome by 2026-03-10: About 1200 mg a day from food by her own three-day food record. **S**
- 25-hydroxyvitamin D of 30 ng/mL or more before the first infusion. Outcome by 2026-05-12: 24 ng/mL at intake and 38 ng/mL at three months. **S**
- First zoledronic acid dose by the three-month visit, with normal calcium and kidney function and a dental check done. Outcome by 2026-05-12: Given at three months after normal calcium (9.5 mg/dL) and eGFR (81) and a routine dental examination. **S**
- Complete the eight-week balance and strength program, with no falls through six months. In progress; target 2026-08-11. **S**
- Serum CTX at least 30 percent lower three months after the first dose. In progress; target 2026-08-11. **S**
- Sustained remission from alcohol use disorder throughout the episode. In progress; target 2026-08-11. **S**

## Medication changes

- Started: Zoledronic acid 5 mg in 100 mL intravenous infusion over 30 minutes, once every 12 months **S**
- Started: Acetaminophen 500 mg oral tablet, two tablets every 6 hours as needed for aches or fever for up to three days after the infusion (no more than 3 g a day) **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026), Aether Forge
- The clinician's guide to prevention and treatment of osteoporosis (2022), Bone Health and Osteoporosis Foundation (LeBoff MS et al., Osteoporos Int 2022;33(10):2049-2102)
- American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis, 2020 Update (2020), AACE/ACE (Camacho PM et al., Endocr Pract 2020;26(Suppl 1):1-46)
- Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline (2019), Endocrine Society (Eastell R et al., J Clin Endocrinol Metab 2019;104(5):1595-1622)
- STEADI: Stopping Elderly Accidents, Deaths, and Injuries (2026), Centers for Disease Control and Prevention
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense

## Follow-up

- Zoledronic acid infusion today. Call the clinic for fever lasting more than three days, muscle cramps or tingling, or jaw pain. Six-month bone health review in three months with fasting CTX and calcium. **S**
- Next scheduled visit 2026-08-11: six-month bone health review, three months after the first infusion. **S**
